公开(公告)号：US12246020B2

公开(公告)日：2025-03-11

申请号：US18517156

申请日：2023-11-22

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yueheng Jiang ,  Yanqin Liu

IPC: C07D487/04 ,  A61K31/505 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  C07D471/04

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

公开(公告)号：US11865115B2

公开(公告)日：2024-01-09

申请号：US17591816

申请日：2022-02-03

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yueheng Jiang ,  Yanqin Liu

IPC: C07D487/04 ,  A61K31/505 ,  A61P35/00 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D471/04 ,  C07B2200/13

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

公开(公告)号：US11685720B2

公开(公告)日：2023-06-27

申请号：US17748134

申请日：2022-05-19

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing Dai ,  Yueheng Jiang

IPC: C07D213/70 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/522

CPC classification number: C07D213/70 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/522 ,  C07B2200/13

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound (1) and its salts (such as sodium, potassium, and calcium salt), as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as gout and hyperuricemia.

公开(公告)号：US11498921B1

公开(公告)日：2022-11-15

申请号：US17499230

申请日：2021-10-12

Applicant: INVENTISBIO CO., LTD.

Inventor： Yueheng Jiang

IPC: C07D403/04 ,  A61P35/02 ,  A61P35/04 ,  A61K31/506 ,  C07D471/04 ,  C07D401/04 ,  C07D403/14 ,  C07D405/14 ,  C07D401/14 ,  C07D413/04 ,  C07D417/04 ,  A61K31/437

Abstract: The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

公开(公告)号：US12173010B2

公开(公告)日：2024-12-24

申请号：US18316471

申请日：2023-05-12

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing Dai ,  Yaolin Wang ,  Yueheng Jiang ,  Yanqin Liu ,  Haotao Niu ,  Zhenwu Wang ,  Zixing Han ,  Liangshan Tao ,  Jifang Weng ,  Zhe Shi

IPC: C07D493/08 ,  A61K31/00 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D487/04

Abstract: Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.

公开(公告)号：US12110289B2

公开(公告)日：2024-10-08

申请号：US17365503

申请日：2021-07-01

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yaolin Wang ,  Yueheng Jiang ,  Yanqin Liu ,  Zhe Shi ,  Zhenwu Wang ,  Liangshan Tao ,  Zixing Han ,  Haotao Niu ,  Jifang Weng

IPC: C07D471/04 ,  A61K31/282 ,  A61K31/438 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/282 ,  A61K31/438 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00 ,  C07D519/00

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

公开(公告)号：US20210261543A1

公开(公告)日：2021-08-26

申请号：US17231581

申请日：2021-04-15

Applicant: INVENTISBIO CO., LTD.

Inventor： Yueheng Jiang

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  C07D401/04 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  A61P35/02 ,  A61P35/04 ,  C07D401/14 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

公开(公告)号：US12227491B2

公开(公告)日：2025-02-18

申请号：US18187430

申请日：2023-03-21

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing Dai ,  Yueheng Jiang

IPC: C07D403/04 ,  A61K9/20 ,  A61K9/48 ,  A61K31/506

Abstract: Provided herein are compounds, salts, solid forms, and pharmaceutical compositions that are related to EGFR inhibitors, such as N-(2-((2-(dimethylanino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, solid forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as cancer.

公开(公告)号：US11903931B2

公开(公告)日：2024-02-20

申请号：US17568324

申请日：2022-01-04

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yueheng Jiang

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K45/06

CPC classification number: A61K31/4375 ,  A61K45/06 ,  C07D471/04 ,  C07B2200/13

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.

公开(公告)号：US20210260067A1

公开(公告)日：2021-08-26

申请号：US17172984

申请日：2021-02-10

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yueheng Jiang ,  Yanqin Liu

IPC: A61K31/519 ,  C07D471/04 ,  A61K45/06

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.